Table 2.
The treatment regimen of neoadjuvant therapy
| Study | Year | NET | NCT | NCET |
|---|---|---|---|---|
| Chae [24] | 2016 | Letrozole qd | FEC, a switch to docetaxel if PD or SD | |
| Wright [25] | 2015 | AIs or tamoxifen qd | PAT or AT | |
| Palmieri [26] | 2014 | Letrozole qd | FE100C or FE75C, a switch to docetaxel if PD or SD | |
| Semiglazov [27] | 2007 | Exemestane or anastrozole qd | Doxorubicin + paclitaxel | |
| Marcus [28] | 2013 | AIs or tamoxifen qd | Anthracycline-based or non-anthracycline-based | |
| Ellis [29] | 2017 | AIs qda | Anthracycline-based or non-anthracycline-based | |
| Nakayama [30] | 2018 | Anastrozole qd | Anastrozole qd + UFT | |
| Sato [31] | 2018 | Exemestane qd | Exemestane qd + cyclophosphamide | |
| Sugiu [32] | 2015 | FEC-T | Exemestane qd + EFC-T | |
| Mohammad [33] | 2012 | FAC | Letrozole qd + FAC |
Explanation of regimen: FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; FE100C, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2; FE75C, 5-fluorouracil 600 mg/m2, cyclophosphamide 600 mg/m2, epirubicin 75 mg/m2; UFT, tegafur/uracil combination in 1:4 M ratio; 270 mg/m2/day in two divided doses; FEC-T, 80 mg/m2 of paclitaxel followed by a combination of fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2; FAC, 5-Fluorouracil 600 mg/m2, doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2
Abbreviations: NET Neoadjuvant endocrine therapy, NCT Neoadjuvant chemotherapy, NCET Neoadjuvant chemoendocrine therapy, AIs Aromatase inhibitors, PD Progressive disease, SD Stable disease
aThese aromatase inhibitors include letrozole, anastrozole and exemestane